Abstract
Summary: Idiopathic pulmonary fibrosis is the most serious prognostic interstitial lung process in adults. So far, patients have been regularly met mainly by pulmonologists, during the ongoing pandemic caused by the new type of coronavirus SARS-CoV-2, which causes covid-19, but doctors of covid units, whose original specialization may be very far from pneumology, may also meet them regularly.
If a patient with idiopathic pulmonary fibrosis is required for covid-19 with moderate or severe course, the prognosis of these patients is significantly worse than that of persons without pre-existing interstitial lung process. However, research into the treatment of covid-19 is also advancing the research of drugs potentially useful in the treatment of idiopathic pulmonary fibrosis and new possibilities for their application.
In particular, the Communication summarizes information on molecules considered for inhalation use in patients with idiopathic pulmonary fibrosis.